EMCDDA. New drugs in Europe, 2012, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2013. 773 kB. #8
EMCDDA. New drugs in Europe, 2010, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2011. 700 kB.
Gwak, S; Arroyo-Mora, LE; Almirall, JR. Qualitative analysis of seized synthetic cannabinoids and synthetic cathinones by gas chromatography triple quadrupole tandem mass spectrometry. Drug Test. Anal., 1 Feb 2015, 7 (2), 121-130. 1.1 MB. https://doi.org/10.1002/dta.1667 #10
Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products. Drug Test. Anal., 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonists as new psychoactive substances: Origins. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 165-190. 906 kB. https://doi.org/10.1007/164_2018_143 #11
Adamowicz, P; Zuba, D. Discrimination among designer drug isomers by chromatographic and spectrometric methods. In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 211–232. 1.1 MB.
Abbate, V; Schwenk, M; Presley, BC; Uchiyama, N. The ongoing challenge of novel psychoactive drugs of abuse. Part I. Synthetic cannabinoids (IUPAC Technical Report). Pure Appl. Chem., 28 Aug 2018, 90 (8), 1255–1282. 1.0 MB. https://doi.org/10.1515/pac-2017-0605 #1. CP 47,497 (C8)
EMCDDA. New drugs in Europe, 2009, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2010. 321 kB. #6
Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #2
Ujváry, I. The bumpy road ahead for forensic scientists. Synthetic cannabinoids to (unwel)come. Spice II Plus, 5 Jun 2014. 405 kB. #CP-47,497 C8
Wouters, E; Walraed, J; Robertson, MJ; Meyrath, M; Szpakowska, M; Chevigné, A; Skiniotis, G; Stove, C. Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. ACS Pharmacol. Transl. Sci., 10 Apr 2020, 3 (2), 285–295. 2.0 MB. https://doi.org/10.1021/acsptsci.9b00069 #1
Alam, RM; Keating, JJ. Adding more “spice” to the pot: A review of the chemistry and pharmacology of newly emerging heterocyclic synthetic cannabinoid receptor agonists. Drug Test. Anal., 1 Mar 2020, 12 (3), 297–315. 2.8 MB. https://doi.org/10.1002/dta.2752 #2 Structure 71 has a single bond where a double bond belongs
Uchiyama, N; Kikura-Hanajiri, R; Shoda, T; Fukuhara, K; Goda, Y. Isomeric analysis of synthetic cannabinoids detected as designer drugs. Yakugaku Zasshi, 1 Jan 2011, 131 (7), 1141–1147. 763 kB. https://doi.org/10.1248/yakushi.131.1141 #1 LC,MS,UV,other